GlassScriptPhysician profile
Daniela M Dicenso
NPI 1194173831
$3,186.16
in general payments reported to CMS, 2019-2025
28 companies · $59.06 in 2025
The $59.06 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2021: $711 · 2022: $1,963 · 2023: $148 · 2024: $25.22 · 2025: $59.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $232.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $561.73 | 2021-2025 | Omnipod |
| Lilly USA, LLC | $428.12 | 2021-2024 | Mounjaro |
| Novo Nordisk INC | $279.00 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $212.35 | 2022 | |
| Tandem Diabetes Care, INC. | $208.23 | 2022 | |
| Amgen INC. | $190.49 | 2019-2022 | |
| Mannkind Corporation | $163.66 | 2021-2022 | |
| Abbott Laboratories | $155.12 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Dexcom, INC. | $122.58 | 2021-2022 | |
| Tanabe Pharma America, INC. | $111.45 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $108.67 | 2022 | |
| Astellas Pharma US INC | $81.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.62 | 2021-2023 | Synjardy |
| Amneal Pharmaceuticals LLC | $72.69 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $61.84 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $49.42 | 2022 | |
| Corcept Therapeutics | $39.67 | 2022-2025 | Korlym |
| Zealand Pharma US, INC. | $35.29 | 2021 | |
| Cequr Corporation | $33.08 | 2022 | |
| Ibsa Pharma INC. | $32.69 | 2021-2022 | |
| Ascensia Diabetes Care US INC. | $24.55 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $24.10 | 2021 | |
| Xeris Pharmaceuticals, INC. | $22.75 | 2022 | |
| Lifescan, INC. | $20.89 | 2022 | |
| Recordati_rare_diseases_inc. | $17.83 | 2022 | |
| Eusa Pharma (US) LLC | $17.83 | 2022 | |
| Radius Health, INC. | $16.25 | 2022 | |
| Vistapharm, INC. | $14.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Dicenso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.